Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WJMSC for Autism
NCT06293950Phase 1Recruiting
- Sponsor
- University of Jordan
- Start
- Mar 2022
- Primary completion
- Jun 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of wharton's jelly mesenchymal stromal cells in Autism Spectrum Disorder (ASD), sponsored by University of Jordan. Primary endpoint: Safety profile lab tests at 12 months. Started Mar 2022; status: recruiting.
02
Drugs
wharton's jelly mesenchymal stromal cells
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT06293950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06293950.